Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: June 2009
-
By Bradley Crawford — On May 19, 2009, Mr. Enrique Molina Galan, one of nine Directors of Biotechnology at the European Patent Office, discussed biotech patent practice before the European Patent Office at BIO 2009. In a presentation entitled "How Is the European Patent Office Supporting Innovation in Europe?" Mr. Molina Galan provided some…
-
By Donald Zuhn — Economist Alex Brill, who last fall released a report on follow-on biologics, is back, this time focusing on proposals for "reforming" the U.S. patent system instead of suggestions for creating a follow-on biologics regulatory pathway. Patent Docs readers may recall that in November, Mr. Brill (at right), a research fellow…
-
By Andrew Williams — On Monday, the Federal Circuit issued its decision in Amgen, Inc. v. Ariad Pharmaceuticals, Inc., dealing another blow to Ariad Pharmaceuticals and U.S. Patent No. 6,410,516, directed to certain aspects of the NF-κB transcription factor pathway. Previously, on April 3, the Federal Circuit held that four of the claims of…
-
By Kevin E. Noonan — The Supreme Court today granted certiorari to the patent applicants in the In re Bilski case, an en banc decision from the Federal Circuit last fall. In doing so, the Court continued its recent history of more direct supervision of the Federal Circuit, a decision made more notable by…
Patent Docs 